Multivariate analysis of chronic GVHD for patients surviving at least 90 days
. | Relative risk of chronic GVHD (95% CI) . | P . |
---|---|---|
HLA-identical sibling BM | ||
G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.10 (0.86-1.39) | .13 |
Age | 1.03 (1.02-1.03) | < .001 |
Other D/R sex combination vs F D/M R* | 0.63 (0.51-0.77) | .001 |
CML vs AML* | 1.36 (1.12-1.66) | .002 |
Year of transplantation | ||
1999 to 2000 vs 1995-1996* | 0.48 (0.35-0.67) | < .001 |
HLA-identical sibling PBSCs | ||
G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.24 (0.94-1.63) | .11 |
Year of transplantation, 1997 to 1998 vs 1995 to 1996* | 0.67 (0.48-0.93) | .02 |
1999 to 2000 vs 1995 to 1996* | 0.67 (0.49-0.94) | < .001 |
KPS more than 80* vs less than 80% | 0.65 (0.46-0.92) | .01 |
Matched unrelated donor BM | ||
G-CSF+ within 7 days after transplantation vs no G-CSF* | 0.85 (0.63-1.15) | .30 |
CML vs AML* | 1.45 (1.05-2.01) | .03 |
Recipient CMV status, negative vs positive* | 0.66 (0.49-0.89) | .007 |
. | Relative risk of chronic GVHD (95% CI) . | P . |
---|---|---|
HLA-identical sibling BM | ||
G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.10 (0.86-1.39) | .13 |
Age | 1.03 (1.02-1.03) | < .001 |
Other D/R sex combination vs F D/M R* | 0.63 (0.51-0.77) | .001 |
CML vs AML* | 1.36 (1.12-1.66) | .002 |
Year of transplantation | ||
1999 to 2000 vs 1995-1996* | 0.48 (0.35-0.67) | < .001 |
HLA-identical sibling PBSCs | ||
G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.24 (0.94-1.63) | .11 |
Year of transplantation, 1997 to 1998 vs 1995 to 1996* | 0.67 (0.48-0.93) | .02 |
1999 to 2000 vs 1995 to 1996* | 0.67 (0.49-0.94) | < .001 |
KPS more than 80* vs less than 80% | 0.65 (0.46-0.92) | .01 |
Matched unrelated donor BM | ||
G-CSF+ within 7 days after transplantation vs no G-CSF* | 0.85 (0.63-1.15) | .30 |
CML vs AML* | 1.45 (1.05-2.01) | .03 |
Recipient CMV status, negative vs positive* | 0.66 (0.49-0.89) | .007 |
BM indicates bone marrow; G-CSF, granulocyte colony stimulating factor; D, donor; R, recipient; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; PBSC, peripheral blood stem cell; KPS, Karnofsky performance status; and CMV, cytomegalovirus.
Reference group